Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder
Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions.
Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
ThermoGenesis Holdings, Inc. (NASDAQ: THMO) shares jumped 80% to $3.7820 after the company announced the roll out of ReadyStart cGMP Suites for early-stage cell and gene-therapy companies.
Psyched: 9 US Reform Bills, Ayahuasca ‘A Release’ For Prince Harry, At-Home Therapy & More
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization
Throughout the 2023 session, numerous discussions have been held and various measures have been considered around the legalization of psychedelics.
Let’s go over the latest proposed regulations.
Here Are The Year’s Highest Priced Psychedelics Stocks In US Markets
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.
Incannex Engages Catalent For Development And Manufacture Of Psilocybin Drug For Clinical Trials
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, has engaged Catalent (NYSE:
Incannex Has Engaged Catalent To Develop And Manufacture A cGMP-grade Psilocybin Drug Product For Use In Incannex’s Proprietary Psilocybin-assisted Psychotherapy Drug Development Program And, Potential Wider Commercial Use
Commencing development and manufacture of a psilocybin drug product follows an internal analysis of the interim data from the PsiGAD phase 2 clinical trial, giving Incannex confidence to proceed with formulation
Incannex Starts Phase 2 Clinical Trial Of CBD-Based Drug For Use In Treatment Of Rheumatoid Arthritis
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has commenced a phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug IHL-675A in patients with rheumatoid arthritis (‘RA’
Incannex Healthcare Has Commenced A Phase 2 Trial To Assess The Safety And Efficacy Of Its Proprietary Anti-inflammatory Combination Drug IHL-675A For Rheumatoid Arthritis
IHL-675A is a proprietary fixed-dose combination drug comprising cannabidiol (CBD) and hydroxychloroquine (HCQ).
Australian Psychedelics: Phase 2 Trial On Psilocybin For Anxiety Will Soon Share Results
Australian biopharma company developing therapeutic cannabinoid products and psychedelic medicines Incannex Healthcare (NASDAQ:
